Conversely, its expression is downregulated in esophageal cancer (which is associated with a reduced immune response), gastric cancer (16) (where it inhibits gastric cancer cell proliferation and promotes cell apoptosis), and ovarian cancer (where it down-regulates Claudin-1), among others. This evidence concerns the gene CLDN1 and gastric cancer.